Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial

  1. Ettl, J.
  2. Quek, R.G.W.
  3. Lee, K.-H.
  4. Rugo, H.S.
  5. Hurvitz, S.
  6. Gonçalves, A.
  7. Fehrenbacher, L.
  8. Yerushalmi, R.
  9. Mina, L.A.
  10. Martin, M.
  11. Roché, H.
  12. Im, Y.-H.
  13. Markova, D.
  14. Bhattacharyya, H.
  15. Hannah, A.L.
  16. Eiermann, W.
  17. Blum, J.L.
  18. Litton, J.K.
Revista:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Any de publicació: 2018

Volum: 29

Número: 9

Pàgines: 1939-1947

Tipus: Article

DOI: 10.1093/ANNONC/MDY257 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus